<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689907</url>
  </required_header>
  <id_info>
    <org_study_id>D18125</org_study_id>
    <nct_id>NCT03689907</nct_id>
  </id_info>
  <brief_title>Early Chimerism Following Allogeneic Stem-Cell Transplant</brief_title>
  <official_title>Assessing the Predictive Potential of Early Chimerism Analysis Following Allogeneic Stem-Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood
      cancers. To determine how much of your cells are from your donor after transplant, doctors
      complete a &quot;chimerism analysis&quot; or a test of your cells to look at the DNA. Chimerism testing
      helps doctors predict graft rejection or recurrence of disease. Doctors at NCCC do chimerism
      testing routinely and it is usually done between 30 and 100 days after transplantation. The
      researchers believe that analyzing chimerism sooner than 30 days after transplant may help
      identify problems earlier, get patients treatment sooner, and increase the chances of a
      successful transplant.

      The purpose of this study is to find out if doing chimerism testing earlier than the
      traditional approach is better for patient outcomes (about 14 days after transplantation
      rather than 30+ days). We hope the information gained from this study can be used to help
      prevent some post-transplant complications such as graft loss, graft-versus-host disease, or
      even relapse for future patients.

      Also, the researchers hope to learn more about chimerism testing of cells of patients with
      haploidentical donors (donors who are only a &quot;half-match&quot; - such as a parent or child of the
      recipient), because there have not been many chimerism analysis studies done in this
      population
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize early lineage-specific chimerism profiles in allogeneic stem-cell transplant recipients</measure>
    <time_frame>14 or 15 days post-transplant</time_frame>
    <description>Our method of chimerism analysis is dependent on baseline DNA samples of pre-transplant donor and recipient, then serial assessment of polymorphic short tandem repeats (STRs) to specifically characterize the source (donor vs recipient) of DNA extracted from our patients' leukocytes at day +14/15 after allogeneic stem cell transplant. First, DNA is extracted from the buffy coat layer of an EDTA blood sample, then PCR reactions using STR markers are prepared, and the differently sized fluorescent PCR products are then assessed on a genetic analyzer. An assessment of the relative amounts of donor and recipient chimerism can then be determined from the analyzer output, based on peak height and area. The discreet leukocyte lineages are then isolated by cell separation, and DNA is isolated from these purified fractions and assessed as for whole blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate early chimersim profiles with donor chimerism</measure>
    <time_frame>Day +30-post transplant</time_frame>
    <description>Day +14/15-post transplant absolute neutrophil count and absolute lymphocyte count will be compared to the Day +30-post transplant lineage-specific chimerism profile to determine if there is a correlation between early lineage chimerism and full donor chimerism.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Allogeneic Stem-Cell Transplant</condition>
  <arm_group>
    <arm_group_label>Allogeneic Stem-Cell Transplant Recipients</arm_group_label>
    <description>At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.
At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chimerism Evaluation</intervention_name>
    <description>Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.</description>
    <arm_group_label>Allogeneic Stem-Cell Transplant Recipients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All participants in this study will receive an allogeneic stem-cell transplant.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients will have been cleared by a Transplant Attending to undergo allogeneic
             stem cell transplant

        Exclusion Criteria:

          -  Patients undergoing a second allogeneic stem cell transplant or beyond
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M. Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Nurse</last_name>
    <phone>(800) 639-6918</phone>
    <email>cancer.research.nurse@dartmouth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Hill, MD</last_name>
      <phone>603-650-4628</phone>
      <email>john.m.hill@hitchcock.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Farhan S, Bazydlo M, Neme K, Mikulandric N, Peres E, Janakiraman N. Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy. Adv Hematol. 2017;2017:8690416. doi: 10.1155/2017/8690416. Epub 2017 Nov 8.</citation>
    <PMID>29250116</PMID>
  </reference>
  <reference>
    <citation>Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017 Jun;52(6):811-817. doi: 10.1038/bmt.2017.34. Epub 2017 Mar 13.</citation>
    <PMID>28287639</PMID>
  </reference>
  <reference>
    <citation>Parmesar K, Raj K. Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies. Adv Hematol. 2016;2016:3905907. doi: 10.1155/2016/3905907. Epub 2016 May 30. Review.</citation>
    <PMID>27313619</PMID>
  </reference>
  <reference>
    <citation>Fabricius WA, Ramanathan M. Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies. Adv Hematol. 2016;2016:5726132. doi: 10.1155/2016/5726132. Epub 2016 Feb 29. Review.</citation>
    <PMID>27034676</PMID>
  </reference>
  <reference>
    <citation>Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19. Review.</citation>
    <PMID>24842530</PMID>
  </reference>
  <reference>
    <citation>Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, Ritz J, Alyea EP 3rd. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct;20(10):1516-21. doi: 10.1016/j.bbmt.2014.05.025. Epub 2014 Jun 4.</citation>
    <PMID>24907627</PMID>
  </reference>
  <reference>
    <citation>Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10.</citation>
    <PMID>25016197</PMID>
  </reference>
  <reference>
    <citation>Mathur, A and Malhotra, H. Haploidentical Stem Cell Transplantation: A Mini Review. J Stem Cell Res Ther 2017; 2(2): 00056.</citation>
  </reference>
  <reference>
    <citation>Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70. doi: 10.1016/j.bbmt.2007.10.025. Review. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8.</citation>
    <PMID>18162238</PMID>
  </reference>
  <reference>
    <citation>Legrand, F et al. Chimerism Analysis after Haploidentical Stem Cell Transplantation: Is It Necessary for All Patients? Blood 2016; 128: 3417.</citation>
  </reference>
  <reference>
    <citation>Hussain, A et al. Lineage-Specific Chimerism and Incidence of Graft Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single Center. Blood 2012; 120: 3030.</citation>
  </reference>
  <reference>
    <citation>Moscardó F, Sanz J, Senent L, Cantero S, de la Rubia J, Montesinos P, Planelles D, Lorenzo I, Cervera J, Palau J, Sanz MA, Sanz GF. Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica. 2009 Jun;94(6):827-32. doi: 10.3324/haematol.2008.000935.</citation>
    <PMID>19483157</PMID>
  </reference>
  <reference>
    <citation>Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D, Kaji M, Sugita J, Shigematsu A, Iwao N, Ota S, Masauzi N, Fukuhara T, Kasai M, Asaka M, Imamura M. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transplant. 2006 May;37(9):837-43.</citation>
    <PMID>16547484</PMID>
  </reference>
  <reference>
    <citation>Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, Lawitschka A, Peters C, Mann G, Lion T, Matthes-Martin S. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2012 Mar;26(3):509-19. doi: 10.1038/leu.2011.244. Epub 2011 Sep 16.</citation>
    <PMID>21926962</PMID>
  </reference>
  <reference>
    <citation>Choi, YB et al. Does Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation Predict Treatment Failure in Children with Non-Malignant Disease? BBMT 2016; 22: S310.</citation>
  </reference>
  <reference>
    <citation>Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001;7(9):473-85. Review.</citation>
    <PMID>11669214</PMID>
  </reference>
  <reference>
    <citation>Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant. 2007 Mar;39(5):285-91. Epub 2007 Jan 29.</citation>
    <PMID>17262061</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>John M. Hill, Jr., MD</investigator_full_name>
    <investigator_title>Director, Allogeneic Bone Marrow Transplant Program</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

